Vaccines,
Год журнала:
2023,
Номер
11(12), С. 1746 - 1746
Опубликована: Ноя. 23, 2023
The
rapid
development
and
implementation
of
COVID-19
vaccines
merit
understanding
its
effects
on
metabolic
indices.
This
retrospective
longitudinal
study
investigated
the
influence
first-to-second-dose
intervals
time
since
final
dose
indices
individuals
receiving
vaccinations.
A
total
318
Saudi
subjects
(59.7%
females)
aged
12-60
years
received
via
national
vaccination
program.
We
collected
anthropometric
data
fasting
blood
samples
at
specific
points
before
after
dose,
biochemical
indices,
including
glucose
lipid
profile,
were
measured.
also
dates
history
during
period.
participants
stratified
into
groups
based
to
compare
pre-and
post-vaccination
changes
in
between
groups.
Logistic
regression
analysis
revealed
no
differences
pre-
status
either
adolescents
or
adults.
However,
shorter
(≤6
months)
follow-up
associated
with
a
decrease
cardiometabolic
components,
especially
triglyceride
levels
(OR
=
0.39,
95%
CI:
(0.22-0.68),
p
<
0.001)
than
longer
(>6
In
conclusion,
duration
was
levels,
indicating
that
improvements
wane
over
time.
Further
research
is
needed
validate
observed
relationship,
as
it
may
contribute
optimizing
vaccine
effectiveness
safety
future.
Biometrics & Biostatistics International Journal,
Год журнала:
2023,
Номер
12(1), С. 23 - 25
Опубликована: Фев. 21, 2023
The
recently
emerged
coronavirus
SARS-COV-2
viral
strain
that
has
caused
COVID-19
illness
is
a
member
of
the
Coronaviridiae
family,
and
well
known
to
produce
respiratory,
gastrointestinal
other
illnesses
in
man
animals.1,2
Although
exact
source
or
origin
not
yet
been
established,
causes
Covid-19
also
genetically
related
some
zoonotic
viruses
isolated
from
pangolin,
bats
camels,
which
have
previously
respiratory
humans.3–5
Thus,
human
infections
likely
could
occurred
an
intermediate
animal
host
via
incidental
interspecies
transmission
unconfirmed
epidemiological
origins
as
believed
with
MERS
strain.
Coronavirus
Sars
2-Cov-19
pandemic
first
Wuhan,
China
on
before
January
2020
spread
worldwide
exponentially
during
Spring
Fall
2020.2
newly
described
infected
millions
people
globally
by
year’s
end
continued
into
2021
present,
interval
multiple
infectious
mutations
evolved,
more
highly
potential
than
initial
virus.
Continuing
outbreaks
mutants
emerged,
often
seemingly
evading
immunities
formed
immunizations
earlier
variants.
purpose
present
editorial
review
overview
progressive
developments
current
propose
application
biophotonic
bioelectromagnetic
therapy
often-effective
adjunct
treatment
potentially
life
threatening
microbial
illnesses.
This
brief
paper
concludes
(treatment)
modalities
utilized
successfully
for
many
years,
prior
development
antimicrobial
antiviral
pharmaceutic
agents
standard
care
common
present-day
therapies
diseases
medRxiv (Cold Spring Harbor Laboratory),
Год журнала:
2023,
Номер
unknown
Опубликована: Апрель 27, 2023
Abstract
Background
The
difficulty
to
predict
fatal
outcomes
in
COVID-19
patients,
impacts
the
general
morbidity
and
mortality
due
SARSCoV2
infection,
as
it
wears
out
hospital
services
that
care
for
these
patients.
Unfortunately,
several
of
candidates
prognostic
biomarkers
proposed,
predictive
power
is
compromised
when
patients
have
pre-existing
co-morbidities.
Methods
A
cohort
one
hundred
forty-seven
hospitalized
severe
COVID19
was
included
a
descriptive,
observational,
single-center,
prospective
study.
Patients
were
recruited
during
first
pandemic
wave
(April-Nov,
2020).
Data
collected
from
clinical
history
while
immunophenotyping
by
multiparameter
flow
cytometry
analysis
allowed
us
assess
expression
surface
markers
on
peripheral
leukocytes.
grouped
according
outcome
survivor
or
decease.
value
leukocytes,
cytokines
HLA-DR,
CD39,
CD73
calculated.
Results
Hypertension
chronic
renal
failure
but
not
obesity
diabetes
conditions
more
frequent
among
decease
group.
Mixed
hypercitokinemia,
including
inflammatory
(IL-6)
anti-inflammatory
(IL-10)
cytokines,
evident
deceased
In
group,
lymphopenia
with
higher
NLR
present.
HLA-DR
percentage
CD39+
cells
than
non
remain
similar
despite
outcome.
ROC
cut-off
(69.6%,
9.4),
pNLR
(71.1%,
13.6),
IL-6
(79.7%,
135.2
pg/mL).
Conclusion
CD73,
many
serum
(other
IL-6)
chemokines
levels
do
show
potential
compared
values.
Vaccines,
Год журнала:
2023,
Номер
11(12), С. 1746 - 1746
Опубликована: Ноя. 23, 2023
The
rapid
development
and
implementation
of
COVID-19
vaccines
merit
understanding
its
effects
on
metabolic
indices.
This
retrospective
longitudinal
study
investigated
the
influence
first-to-second-dose
intervals
time
since
final
dose
indices
individuals
receiving
vaccinations.
A
total
318
Saudi
subjects
(59.7%
females)
aged
12-60
years
received
via
national
vaccination
program.
We
collected
anthropometric
data
fasting
blood
samples
at
specific
points
before
after
dose,
biochemical
indices,
including
glucose
lipid
profile,
were
measured.
also
dates
history
during
period.
participants
stratified
into
groups
based
to
compare
pre-and
post-vaccination
changes
in
between
groups.
Logistic
regression
analysis
revealed
no
differences
pre-
status
either
adolescents
or
adults.
However,
shorter
(≤6
months)
follow-up
associated
with
a
decrease
cardiometabolic
components,
especially
triglyceride
levels
(OR
=
0.39,
95%
CI:
(0.22-0.68),
p
<
0.001)
than
longer
(>6
In
conclusion,
duration
was
levels,
indicating
that
improvements
wane
over
time.
Further
research
is
needed
validate
observed
relationship,
as
it
may
contribute
optimizing
vaccine
effectiveness
safety
future.
